TCT 2015: Minnetronix Showcases Next-Generation Technology for Mechanical Circulatory Support
October 23, 2015 - Aaron McCabe, Director of Research and Development, Neurocritical Care
Last week, a Minnetronix team journeyed west to San Francisco to participate in the 2015 Transcatheter Cardiovascular Therapeutics (TCT) conference. TCT is the world’s largest educational meeting specializing in interventional cardiovascular medicine, with more than 10,000 attendees. Minnetronix attended TCT in order to showcase our vast experience in mechanical circulatory support (MCS) power and control and to further our own knowledge about new developments in this space.
The six-day conference was loaded with scientific sessions, roundtables, discussions, and debates. For those of us from Minnetronix, we were particularly interested in talks on heart assist therapies, including left ventricular assist devices (LVADs), percutaneous VADs (pVADs), counterpulsation, and right heart assist. We enjoyed the “Shark Tank” style session on Interventional Innovation that put device entrepreneurs in front of an experienced panel of medical VC “sharks”. Popular areas of market interest from the shark tank participants included:
- Renal denervation
- Pulmonary hypertension
- Data and digital health
- Heart failure
- Consumer level (e.g. CVS and Walgreens)
At the Minnetronix booth, we exhibited our percutaneous ventricular assist device (pVAD) and VAD technologies. The new animation highlighting our MCS technologies drew attention and questions from physicians, industry representatives, academia, and distributors. In particular, our proprietary pVAD concept, which consists of a collapsible catheter and impeller that is expanded post-deployment, generated some interesting conversations.
TCT was a great audience for Minnetronix. It was the first time we publicly announced our pVAD technology, and it offered us a terrific opportunity to continue to demonstrate our ongoing commitment to next-generation mechanical circulatory support.